医学
嵌合抗原受体
淋巴瘤
正电子发射断层摄影术
细胞疗法
放射治疗
肿瘤科
免疫疗法
内科学
放射科
细胞
癌症
遗传学
生物
作者
Vanessa Murad,Andrés Kohan,Claudia Ortega,Anca Prica,Patrick Veit‐Haibach,Ur Metser
出处
期刊:American Journal of Roentgenology
[American Roentgen Ray Society]
日期:2024-03-01
卷期号:222 (3)
被引量:4
摘要
Chimeric antigen receptor (CAR) T-cell therapy is a cellular therapy in which the patient's T cells are enhanced to recognize and bind to specific tumor antigens. CAR T-cell therapy was initially developed for the treatment of leukemia, but its current main indication is the treatment of relapsed or refractory non-Hodgkin lymphoma. FDG PET/CT plays a fundamental role in the diagnosis, staging, therapy response assessment, and recurrence evaluation of patients with metabolically active lymphoma. Consistent with the examination's role in lymphoma management, FDG PET/CT is also the imaging modality of choice to evaluate patients before and after CAR T-cell therapy, and evidence supporting its utility in this setting continues to accumulate. In this article, we review current concepts in CAR T-cell therapy in patients with lymphoma, emphasizing the critical role of FDG PET/CT before and after therapy. A framework is presented that entails performing FDG PET/CT at four time points over the course of CAR T-cell therapy: pretherapy at baseline at the time of decision to administer CAR T-cell therapy and after any bridging therapies and posttherapy 1 and 3 months after infusion. PET parameters assessed at these time points predict various patient outcomes.
科研通智能强力驱动
Strongly Powered by AbleSci AI